At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium
In Brief
A Phase 4 clinical trial evaluating Intravenous Infusion of Diclofenac Sodium and Intravenous Infusion of Placebo for Hypopituitarism. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The effects of acute administration of non-steroidal anti-inflammatory drugs (NSAIDs) on the neuroendocrine regulation of hydro-electrolytic metabolism are not precisely known to date. Although the mechanism by which NSAIDs favor the antidiuretic action of vasopressin (AVP) in the kidney has been partially elucidated, their influence on the mechanisms responsible for regulating its secretion are less known. The interactions between NSAIDs and natriuretic peptides are also not entirely certain. The present pharmacological research study therefore aims to investigate, in a cohort of healthy subjects, the acute effects of intravenous infusion of diclofenac sodium on the neuroendocrine regulation systems of water and salt balance (i.e. the antidiuretic axis and the system of natriuretic peptides).
Study Details
Timeline
Interventions
Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.